Investigational drug · Phase 2
TAVO101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "TAVO101"
First trial start
2024
Mar 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAVO101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "TAVO101" as an intervention, largest first.
Tavotek BiotherapeuticsIndustry
NCT05298046 · 42 participants · Start May 11, 2022 · Primary completion Jun 1, 2024
Drug: Experimental: TAVO101 · For: Healthy Subjects
Sites: Adelaide, Australia
- A Study of TAVO101 in Atopic Dermatitis PatientsActive, not recruiting
Tavotek BiotherapeuticsIndustry
NCT06176040 · 20 participants (planned) · Start Mar 15, 2024 · Primary completion Mar 15, 2025
Drug: TAVO101 · For: Atopic Dermatitis
Sites: Parkville, Australia; Auckland, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
- Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition.
Corren J, Borish L, Brightling C, et al. · J Allergy Clin Immunol 2026
- A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases.
Shi L, Yu M, Jin Y, et al. · Front Immunol 2024
- Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti-Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions.
Han C, Fung I, Zhang D, et al. · J Clin Pharmacol 2024
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.